International Journal of Endocrinology / 2013 / Article / Tab 1

Clinical Study

Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY)

Table 1

Baseline characteristics in each group.

ParametersTelmisartanLosartanP-value

(male/female) 12 (6/6)7 (3/4)
Age (years) 0.612
Duration of diabetes (years) 0.523
Height (cm) 0.673
Body mass index (kg/m2) 0.735
Waist circumference (cm) 0.899
Hip circumference (cm) 0.257
Systolic blood pressure (mmHg) 0.526
Diastolic blood pressure (mmHg) 0.611
Pulse (beats/min) 0.205
Biochemical markers
 Fasting plasma glucose (mg/dL) 0.571
 Hemoglobin A1c (%) 0.444
 Glycoalbumin (%) 0.447
 Immunoreactive insulin (μU/mL) 0.955
 Total cholesterol (mg/dL) 0.447
 High-density lipoprotein cholesterol (mg/dL) 0.290
 Triglyceride (mg/dL) 0.866
 Free fatty acids (mEq/L) 0.001
 Aspartate aminotransferase (IU/L) 0.372
 Alanine aminotransferase (IU/L) 0.583
γ Glutamyl transpeptidase (IU/L) 0.612
 Alkaline phosphatase (IU/L) 0.800
 Lactate dehydrogenase (IU/L) 0.353
 Blood urea nitrogen (mg/dL) 0.704
 Creatinine (mg/dL) 0.283
 Uric acid (mg/dL) 0.582
 Na (mEq/L) 0.447
 K (mEq/L) 0.966
 u-Microalbumin (μg/mL) 0.375
 Ferritin (ng/mL) 0.767
 Creatine phosphokinase (IU/L) 0.899
HOMA-IR 0.865
HOMA-β 0.865
Complete blood count
 White blood cells (×103/μL) 0.052
 Hemoglobin (g/dL) 0.865
 Platelets (×103/μL) 0.163
Inflammatory markers
 Hyaluronic acid (ng/mL) 0.446
 7S domain of type 4 collagen (ng/mL) 0.445
 High-sensitivity CRP (mg/dL) 0.964
 Procollagen-3-peptide (U/mL) 0.175
 Zn (μg/dL) 0.612
 Total adiponectin (μg/mL) 0.400
 Interleukin-6 (pg/mL) 0.309
Bile acids (BA)
 Total BA (μmol/L) 0.331
 Primary BA (μmol/L) 0.135
 Secondary BA (μmol/L) 0.966
CT scan
 Visceral fat (cm2) 0.673
 Subcutaneous fat (cm2) 0.877
 V/S ratio 0.612
 CT-L1 (HU) 0.025
 CT-L2 (HU) 0.063
 CT-Spleen (HU) 0.866
 L/S ratio 0.035
Baseline treatment for hypertension [ (%)]0.973
 Naive5 (41.7)3 (42.9)
 Other ARB or ACE inhibitor3 (25.0)2 (28.6)
 Calcium channel blocker4 (33.3)2 (28.6)
Baseline treatment for diabetes mellitus [ (%)]0.123
 Diet only12 (100.0)5 (71.4)
 Sulphonylurea+α-glucosidase inhibitor0 (0.0)2 (28.6)
Baseline treatment for lipid abnormality [ (%)]0.603
 Diet only10 (83.3)5 (71.4)
 HMG-CoA reductase inhibitor (statin)2 (16.7)2 (28.6)

Data are mean ± SD. Parameters were compared between groups (telmisartan versus losartan) by Mann-Whitney test or chi-squared test.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.